Rigel Pharmaceuticals (RIGL) Other Accumulated Expenses (2010 - 2026)

Rigel Pharmaceuticals' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $9.7 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 29.99% year-over-year to $9.7 million in Q1 2026; TTM through Mar 2026 was $9.7 million, a 29.99% increase from a year earlier, with the FY2025 full-year figure at $11.5 million, down 2.43% from the prior year.
• Other Accumulated Expenses declined to $9.7 million in Q1 2026 per RIGL's latest filing, from $11.5 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $17.6 million in Q3 2022 and bottomed at $1.0 million in Q1 2024.
• The 5-year median for Other Accumulated Expenses is $8.6 million (2025), against an average of $8.6 million.
• Across the five-year window, Other Accumulated Expenses sank 82.15% in 2024 and surged 641.97% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $5.0 million in 2022, then advanced by 6.74% to $5.3 million in 2023, then surged by 120.3% to $11.8 million in 2024, then declined by 2.43% to $11.5 million in 2025, then declined by 15.63% to $9.7 million in 2026.
• Per Business Quant, the three latest RIGL Other Accumulated Expenses figures stand at $9.7 million (Q1 2026), $11.5 million (Q4 2025), and $8.9 million (Q3 2025).